CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, commercializing, and maximizing the potential of proprietary acute-care products in the hospital setting, today announced that it successfully secured a credit facility with leading financial organizations. This debt financing was led by Merrill Lynch Capital Healthcare Finance Group, a division of Merrill Lynch Business Financial Services Inc. who previously participated, as an investor, in EKR’s recent Series C funding round. Also taking part in today’s announced financing was SVB Silicon Valley Bank, the commercial banking arm of SVB Financial Group.
